10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO

7. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q1 2025: 91

Johnson & Johnson (NYSE:JNJ)’s shares are up by 5% since its latest earnings report, which saw it post $23.7 billion in sales to beat analyst estimates of $22.8 billion. Crucially, the shares were helped by Johnson & Johnson (NYSE:JNJ)’s midpoint annual revenue guidance, which the firm raised by $2 billion, and by its midpoint full year EPS of $10.85, which marked a 25-cent jump. Cramer was impressed by Johnson & Johnson (NYSE:JNJ)’s results and shared that the firm surprised on 15 different metrics:

“And then yesterday, unheard and unsung, but we’re going to change that. Johnson & Johnson. Johnson & Johnson delivered a quarter, I counted 15 separate surprises. . .15 different things. That they beat on. All sorts of different metrics.”

Previously, he discussed Johnson & Johnson (NYSE:JNJ)’s prospects ahead of the earnings release:

“Johnson & Johnson kicks off pharma earnings season on Wednesday, and I think once again, the company will not be rewarded for its consistency or its originality because there’s still the sort of the talc lawsuits hanging over it. I don’t mind JNJ fighting the plaintiff’s part, but it sure puts a damper on the stock.”